Lucid Diagnostics Appoints John R. Palumbo to Board

The latest announcement is out from Lucid Diagnostics ( (LUCD) ).

On September 25, 2025, Lucid Diagnostics announced the appointment of John R. Palumbo to its Board of Directors, effective September 22, 2025. Palumbo brings 40 years of healthcare leadership experience, including guiding early-stage companies through commercial growth. His appointment is expected to support Lucid’s strategic initiatives as it approaches key commercial milestones, particularly in addressing unmet needs in cancer prevention with its EsoGuard product.

The most recent analyst rating on (LUCD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Spark’s Take on LUCD Stock

According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.

Lucid Diagnostics’ overall stock score is primarily impacted by its financial performance, which is challenged by high leverage and negative cash flows despite strong revenue growth. The technical analysis suggests a bearish trend, and the valuation is unattractive due to a negative P/E ratio. The earnings call provides some optimism with strategic partnerships and potential Medicare coverage, but operational challenges remain significant.

To see Spark’s full report on LUCD stock, click here.

More about Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer. Lucid offers the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, which are designed for early detection of esophageal precancer.

Average Trading Volume: 1,289,117

Technical Sentiment Signal: Sell

Current Market Cap: $142.7M

See more insights into LUCD stock on TipRanks’ Stock Analysis page.